Key result
New treatment modalities, such as direct thrombin inhibitors and antibodies to platelet glycoprotein IIb/IIIa, appear more effective for prophylaxis and treatment than conventional therapies.
Why the study?
Are new pharmacological modalities (direct thrombin inhibitors, glycoprotein IIb/IIIa inhibitors) more effective than conventional therapies for preventing thromboembolic complications in endovascular procedures?
Are new pharmacological modalities (direct thrombin inhibitors, glycoprotein IIb/IIIa inhibitors) more effective than conventional therapies for preventing thromboembolic complications in endovascular procedures?
Direct thrombin inhibitors and glycoprotein IIb/IIIa inhibitors may offer superior prophylaxis against thromboembolic complications during endovascular procedures compared to conventional therapies.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for direct thrombin inhibitors and GP IIb/IIIa antibodies in endovascular procedures; randomized trials required before practice change.
Thromboembolic and ischemic complications frequently occur during and after endovascular procedures, because of associated arterial injury and the thrombogenic characteristics of arterial catheters, contrast agents, and implanted devices such as coils and stents. Platelet adhesion, activation, and aggregation occurring at the site of arterial injury are mediated by local factors, including thromboxane A2 (inhibited by aspirin) and adenosine diphosphate (inhibited by ticlopidine and clopidogrel). Concomitantly, thrombin is formed by serial activation of clotting factors via contact with subendothelial tissue factor. Thrombin cleaves fibrinogen into fibrin. Thrombin activation is indirectly blocked by heparin and its analogs. However, after thrombin is clot-bound (with fibrin), it is relatively protected from heparin and is effectively blocked only by direct thrombin inhibitors (hirudin and its analogs). The final common pathway in clot formation is the binding of fibrinogen to platelets via platelet glycoprotein IIb/IIIa receptors, which is inhibited by antibodies to platelet IIb/IIIa receptors. New treatment modalities, such as the use of direct thrombin inhibitors and antibodies to platelet glycoprotein IIb/IIIa, seem to be more effective for prophylaxis and treatment than conventional anticoagulation and antiplatelet therapies.
No takes yet. Share an insight, caveat, or question.
Qureshi et al. (2000) conducted a review in Thromboembolic and ischemic complications associated with endovascular procedures. Pharmacological therapies (direct thrombin inhibitors, glycoprotein IIb/IIIa inhibitors) vs. Conventional anticoagulation and antiplatelet therapies was evaluated. New treatment modalities, such as direct thrombin inhibitors and antibodies to platelet glycoprotein IIb/IIIa, appear more effective for prophylaxis and treatment than conventional therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: